References
- Tallarida CS, Egan E, Alejo GD, Raffa R, Tallarida RK, Rawls SM. Levamisole and cocaine synergism: a prevalent adulterant enhances cocaine's action in vivo. Neuropharmacology. 2014;79:590–5. doi:10.1016/j.neuropharm.2014.01.002.
- World Health Organization. List of essential medicines. 21st ed. Geneva: WHO; 2019. p. 6.
- Aggrawal A. Textbook of forensic medicine and toxicology. 1st ed. New Delhi: Avicahl; 2014. p. 605.
- Lee KC, Ladizinski B, Federman DG. Complications associated with use of levamisole-contaminated cocaine: an emerging public health challenge. Mayo Clin Proc. 2012;87(6):581–6. doi:10.1016/j.mayocp.2012.03.010.
- Chen LY, Lin YL, Chiang BL. Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells. Clin Exp Immunol. 2008;151(1):174–81. doi:10.1111/j.1365-2249.2007.03541.x.
- Zhu NY, LeGatt DF, Turner AR. Agranulocytosis after consumption of cocaine adulterated with levamisole. Ann Intern Med. 2009;150(4):287–9. doi:10.7326/0003-4819-150-4-200902170-00102.
- Raheemullah A, Melhem M, Andruska N. Cocaine cessation for levamisole-induced vasculitis. J Clin Rheumatol. 2019.
- Carlson AQ, Tuot DS, Jen K-Y, Butcher B, Graf J, Sam R, Imboden JB. Pauci-immune glomerulonephritis in individuals with disease associated with levamisole-adulterated cocaine: a series of 4 cases. Medicine (Baltimore). 2014;93(17):290–7. doi:10.1097/MD.0000000000000090.
- Czuchlewski DR, Brackney M, Ewers C, Manna J, Fekrazad MH, Martinez A, Nolte KB, Hjelle B, Rabinowitz I, Curtis BR, et al. Clinicopathologic features of agranulocytosis in the setting of levamisole-tainted cocaine. Am J Clin Pathol. 2010;133(3):466–72. doi:10.1309/AJCPOPQNBP5THKP1.
- Tindle HA, Newhouse PA, Freiberg MS. Beyond smoking cessation: investigation medicinal nicotine to prevent and treat COVID-19. Nicotine Tob Res. 2020; May 8.